Another busy week in the psychedelic sector, with many smaller companies not always covered here at Equity Guru making news. Let’s start with the biggest players though. Mind Medicine…
MYCO.C
Mydecine Innovations (MYCO.NE) announced they are filing a new patent for their MDMA-like compounds. In the press release Mydecine writes that “this expansive patent would allow Mydecine to scale…
Mydecine Innovations Group (MYCO.C) announced that they have received approval from Health Canada to significantly expand their cultivation capacity at their Canadian Current Good Manufacturing Practice (cGMP) facility at…
Mydecine (MYCO.C), an upcoming biopharma and life sciences company advocating for the therapeutic use of psychedelic mushrooms, has successfully completed the world’s first legal international export of psilocybin mushrooms….
Mydecine Innovations Group (MYCO.C) expanded their relationship with Applied Pharmaceutical Innovation (API) to include the University of Alberta in support of multiple drug development and clinical trials, according to…
Mydecine Innovations Group (MYCO.C) announced that they were sponsoring a study called “The neurocognitive effects of low dose psychoactive substances,” at Macquary University in Australia today, according to a…
Shroom BOOM! MindMed has been one of the talk on the street, with price jumping over 50% this month and market cap exceeding 1 Billion! Shroom stocks have been…
Mydecine Innovations Group (MYCO.C) launched Mindleap Health, a digital telehealth mobile application today. The intent behind Mindleap is to increase access to mental health services and provide analytics and…
Mydecine Innovations Group’s (MYCO.C) subsidiary Mindleap Health expanded its digital therapeutic services, dealing specifically with addiction, by adding three new programs to its platform. This company is no stranger…
War is a part of human nature. It’s the greatest driver of human innovation, and if we’re inclined to be cynical we could state that it’s the key reason…